Pierre M. Quartier

Paris, 75015, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 215 publications

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update.

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update.

Journal: Joint bone spine

Published: April 10, 2026

AMETHYST: a Retrospective Cohort Study of Treatment Patterns and Outcomes in Patients With Glucocorticoid-refractory Macrophage Activation Syndrome Complicating Still's Disease.

AMETHYST: a Retrospective Cohort Study of Treatment Patterns and Outcomes in Patients With Glucocorticoid-refractory Macrophage Activation Syndrome Complicating Still's Disease.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: January 21, 2026

Marked regression of calcinosis with canakinumab in hyperphosphatemic familial tumoral calcinosis.

Marked regression of calcinosis with canakinumab in hyperphosphatemic familial tumoral calcinosis.

Journal: JBMR plus

Published: December 05, 2025

Characteristics of JIA-associated uveitis at the age of transition.

Characteristics of JIA-associated uveitis at the age of transition.

Journal: Pediatric rheumatology online journal

Published: November 24, 2025

Pharmacological stabilization of hypoxia-inducible factor 1-α dampens the interferon response and promotes glycolysis in Aicardi-Goutières syndrome.

Pharmacological stabilization of hypoxia-inducible factor 1-α dampens the interferon response and promotes glycolysis in Aicardi-Goutières syndrome.

Journal: Nature communications

Published: November 04, 2025

Development and validation of clinical criteria for the definition of disease activity in adult-onset Still's disease: a cohort study.

Development and validation of clinical criteria for the definition of disease activity in adult-onset Still's disease: a cohort study.

Journal: The Lancet. Rheumatology

Published: October 19, 2025

Dazukibart for the treatment of severe TIF1γ-positive juvenile dermatomyositis.

Dazukibart for the treatment of severe TIF1γ-positive juvenile dermatomyositis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: July 17, 2025

Dazukibart for the treatment of severe TIF1γ-positive juvenile dermatomyositis.

Dazukibart for the treatment of severe TIF1γ-positive juvenile dermatomyositis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: July 17, 2025

Systemic juvenile idiopathic arthritis. Pediatric-onset Still's disease

Systemic juvenile idiopathic arthritis. Pediatric-onset Still's disease

Journal: La Revue du praticien

Published: June 23, 2025

Biotherapies for juvenile idiopathic arthristis

Biotherapies for juvenile idiopathic arthristis

Journal: La Revue du praticien

Published: June 23, 2025

IFN-α levels correlate with muscle disease activity only in juvenile dermatomyositis patients with anti-MDA5+ autoantibodies.

IFN-α levels correlate with muscle disease activity only in juvenile dermatomyositis patients with anti-MDA5+ autoantibodies.

Journal: Rheumatology (Oxford, England)

Published: June 03, 2025

French protocol for the diagnosis and management of juvenile idiopathic arthritis including pediatric-onset Still's disease.

French protocol for the diagnosis and management of juvenile idiopathic arthritis including pediatric-onset Still's disease.

Journal: La Revue de medecine interne

Published: May 18, 2025

Showing 1-12 of 215

Last Updated: 09/26/2026